Filter By Category
Archives
Share on -
AZIRKITUG
Generic Name: AZIRKITUG
ABSTRACT -
Azirkitug, also known as ABBV-514 or PR-1925514, is an investigational humanized IgG1-kappa monoclonal antibody targeting CCR8. It is being studied alone and in combination with other agents in advanced solid tumours. As a monoclonal antibody, it has a protein macromolecular structure rather than a small-molecule skeletal formula. Development/regulatory status: Investigational phase 1 oncology agent.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- No approved routine dosing schedule is established.
- Administration must follow the oncology clinical-trial protocol, generally by intravenous infusion.
- Dose escalation, premedication, combination therapy, and dose modifications are protocol-specific.
- Do not use outside regulated clinical research or approved specialist care.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Infusion-related reactions, fever, chills, hypotension, or rash
- Fatigue, nausea, diarrhoea, appetite loss, or headache
- Immune-mediated inflammation affecting skin, gut, liver, lung, endocrine organs, or other tissues
- Cytopenias, infection risk, or laboratory abnormalities
- Hypersensitivity reactions
ALLERGIC REACTIONS -
Hypersensitivity to azirkitug or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azirkitug should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- Checkpoint inhibitors or other immunotherapies may increase immune-mediated adverse reactions.
- Corticosteroids or immunosuppressants may be required for toxicity but can alter immune activity.
- Chemotherapy, radiation, and biologics require protocol-specific review.
- Patients should disclose all medicines, vaccines, supplements, and investigational products.
PREAUTIONS–
- Administer in centres able to manage infusion reactions and immune-related toxicities.
- Monitor vital signs, blood counts, liver enzymes, renal function, endocrine symptoms, and pulmonary symptoms.
- Use caution with active autoimmune disease, uncontrolled infection, pregnancy, or lactation.
WARNINGS –
- Can cause serious infusion reactions and immune-mediated adverse events.
- Seek urgent care for breathing difficulty, severe diarrhoea, jaundice, chest pain, high fever, or severe rash.
- Keep out of reach of children.
Share on -
. Developed by